A 6 Months NIS to Evaluate the Use of Rescue Medication and Quality of Life in Adult Asthmatic Subjects Treated With Symbicort SMART 1-2 Inhalations b.i.d. as Maintenance Therapy Plus Additional Inhalations as-Needed, Compared to Patients Treated With a Free Combination of an Inhaled Glucocorticosteroid and an Inhaled Long Acting beta-2-Agonist Plus as Needed Inhalations of a Short Acting beta-2 Agonist.

Trial Profile

A 6 Months NIS to Evaluate the Use of Rescue Medication and Quality of Life in Adult Asthmatic Subjects Treated With Symbicort SMART 1-2 Inhalations b.i.d. as Maintenance Therapy Plus Additional Inhalations as-Needed, Compared to Patients Treated With a Free Combination of an Inhaled Glucocorticosteroid and an Inhaled Long Acting beta-2-Agonist Plus as Needed Inhalations of a Short Acting beta-2 Agonist.

Completed
Phase of Trial: Phase IV

Latest Information Update: 28 Oct 2015

At a glance

  • Drugs Budesonide/formoterol (Primary) ; Beta 2 adrenergic receptor agonists; Corticosteroids
  • Indications Asthma
  • Focus Therapeutic Use
  • Sponsors AstraZeneca
  • Most Recent Events

    • 02 Dec 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 14 Nov 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 15 Oct 2009 Planned number of patients changed from 600 to 500 as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top